Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Daiichinkyo CoMEX:4568N 79 Operating Margin % is 14.81% as of Jun. 2026, which is 58% above its 10-year median of 9.37. GuruFocus rates MEX:4568N with a GF Score™ of 79/100 and a GF Value™ of MXN602.55. The stock has 3 warning signs investors should review. Among 961 Drug Manufacturers companies, Daiichinkyo Co ranks better than 54.84% on this metric.
Daiichi Sankyo Co Ltd operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for Daiichinkyo Co's Operating Margin % or its related term are showing as below:
MEX:4568N'
s Operating Margin % Range Over the Past 10 Years
Min: 6.63 Med: 9.37 Max: 17.6
Current: 9.78
MEX:4568N's Operating Margin % is ranked better than 54.84% of 961
companies
in the Drug Manufacturers industry
Industry Median: 7.59
vs MEX:4568N: 9.78
Daiichinkyo Co's 5-Year Average Operating Margin % Growth Rate was 17.20% per year.
Daiichinkyo Co's Operating Income for the
three
months ended in Jun. 2026 was MXN9,236 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was MXN24,940 Mil.
Daiichinkyo Co (MEX:4568N) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Daiichinkyo Co Operating Margin % Related Terms
Daiichinkyo Co Operating Margin % Historical Data
* Premium members only.
The historical data trend for Daiichinkyo Co's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:4568N vs LLY, JNJ, ABBV: Operating Margin % Comparison
For the Drug Manufacturers - General subindustry, Daiichinkyo Co's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daiichinkyo Co Operating Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Daiichinkyo Co's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Daiichinkyo Co's Operating Margin % for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Daiichinkyo Co (MEX:4568N) has a Operating Margin % of 14.81% as of Jun. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Daiichinkyo Co and its competitors. This is 58% above median its historical median of 9.37. Over the past decade, Daiichinkyo Co's Operating Margin % has ranged from 6.63 to 17.60. According to the industry distribution chart, Daiichinkyo Co ranks #434 out of 961 companies in the Drug Manufacturers industry, placing it in the top 45.2%.
Is Daiichinkyo Co's Operating Margin % too high?
Daiichinkyo Co's current Operating Margin % of 14.81% is 58% above median its 10-year median of 9.37. Over the past 10 years, this metric has ranged from a low of 6.63 to a high of 17.60. The Drug Manufacturers industry median Operating Margin % is 7.59. Daiichinkyo Co's value of 14.81% is 95.1% above this industry median. Based on the distribution chart, Daiichinkyo Co ranks #434 out of 961 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Daiichinkyo Co has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Daiichinkyo Co's Operating Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Daiichinkyo Co ranks #434 out of 961 companies for Operating Margin %. This puts Daiichinkyo Co in the upper half of its industry. The industry median Operating Margin % is 7.59. Daiichinkyo Co's value of 14.81% is 95.1% above this benchmark. Historically, Daiichinkyo Co's own Operating Margin % has ranged from 6.63 to 17.60 over the past decade. While the company's 10-year median is 9.37 vs. the industry median of 7.59, Daiichinkyo Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.59, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Daiichinkyo Co's current Operating Margin % of 14.81% is 95.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Daiichinkyo Co and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Daiichinkyo Co's current Operating Margin % is 14.81%, which is 58% above median its own 10-year median of 9.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daiichinkyo Co stock overvalued right now?
Daiichinkyo Co (MEX:4568N) has a current Operating Margin % of 14.81%. The stock's GF Value™ is MXN602.55, compared to a current price of MXN286.67 — trading 52.4% below its estimated fair value. The current Operating Margin % is 14.81%, which is 58% above median its 10-year median of 9.37 and 95.1% above the Drug Manufacturers industry median of 7.59. Daiichinkyo Co's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Daiichinkyo Co (MEX:4568N), the current Operating Margin % is 14.81% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Daiichinkyo Co (MEX:4568N) Overvalued in 2026?
Based on GuruFocus' analysis, Daiichinkyo Co stock appears to be undervalued.
The current stock price of MXN286.67 is trading 52.4% below its estimated GF Value™ of MXN602.55.
Key valuation signals for MEX:4568N:
Operating Margin %: 14.81% (58% above median its 10-year median of 9.37)
GF Value™: MXN602.55 vs. price of MXN286.67 (52.4% below fair value)
Industry Position: 95.1% above the Drug Manufacturers median (#434 of 961)
No single metric tells the full story. See the MEX:4568N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2024, approximately one quarter of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its lead ADCs are Enhertu (HER2), Datroway (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu was first approved in the US in December 2019, and Datroway was first approved in January 2025.
79GF Score
Get the complete analysis for MEX:4568N
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:4568N has been successfully added to your 
